X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2152) 2152
Publication (67) 67
Book Review (33) 33
Book Chapter (5) 5
Conference Proceeding (3) 3
Magazine Article (2) 2
Book / eBook (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1692) 1692
female (1011) 1011
male (960) 960
methylprednisolone - administration & dosage (841) 841
pulse therapy, drug (827) 827
adult (666) 666
treatment outcome (639) 639
index medicus (617) 617
middle aged (580) 580
methylprednisolone (442) 442
rheumatology (335) 335
drug therapy, combination (317) 317
methylprednisolone - therapeutic use (314) 314
glucocorticoids - administration & dosage (310) 310
aged (305) 305
corticosteroids (282) 282
adolescent (281) 281
child (275) 275
methylprednisolone pulse therapy (273) 273
immunosuppressive agents - therapeutic use (253) 253
cyclophosphamide (250) 250
therapy (237) 237
pulse therapy (225) 225
retrospective studies (220) 220
prednisolone - administration & dosage (218) 218
immunosuppressive agents - administration & dosage (214) 214
urology & nephrology (213) 213
cyclophosphamide - administration & dosage (206) 206
glucocorticoids - therapeutic use (203) 203
pediatrics (198) 198
medicine, general & internal (190) 190
children (184) 184
anti-inflammatory agents - administration & dosage (178) 178
care and treatment (176) 176
pulse methylprednisolone (174) 174
disease (173) 173
systemic lupus erythematosus (172) 172
methylprednisolone - adverse effects (169) 169
cyclophosphamide - therapeutic use (164) 164
child, preschool (163) 163
magnetic resonance imaging (159) 159
medicine & public health (158) 158
administration, oral (154) 154
infusions, intravenous (148) 148
follow-up studies (146) 146
injections, intravenous (146) 146
lupus nephritis - drug therapy (146) 146
severity of illness index (146) 146
time factors (145) 145
pulse cyclophosphamide (144) 144
nephritis (142) 142
prognosis (136) 136
ophthalmology (131) 131
steroid pulse therapy (129) 129
erythematosus (126) 126
controlled trial (121) 121
lupus nephritis (119) 119
recurrence (118) 118
young adult (118) 118
management (117) 117
dose-response relationship, drug (116) 116
drug therapy (116) 116
biopsy (115) 115
anti-inflammatory agents - therapeutic use (109) 109
prednisone (109) 109
risk factors (108) 108
drug administration schedule (104) 104
prospective studies (104) 104
lupus erythematosus, systemic - drug therapy (103) 103
remission induction (98) 98
acute disease (97) 97
prednisolone (96) 96
glomerulonephritis (95) 95
glucocorticoids - adverse effects (95) 95
steroids (95) 95
mycophenolate-mofetil (94) 94
disease progression (91) 91
dermatology (90) 90
diagnosis (90) 90
combined modality therapy (89) 89
lupus erythematosus, systemic - complications (88) 88
intravenous cyclophosphamide (87) 87
lupus (86) 86
iga nephropathy (85) 85
immunosuppressive agents - adverse effects (85) 85
research (85) 85
controlled-trial (81) 81
efficacy (80) 80
clinical neurology (79) 79
infant (79) 79
rheumatoid-arthritis (77) 77
dosage and administration (76) 76
endocrinology & metabolism (76) 76
health aspects (73) 73
immunology (73) 73
aged, 80 and over (72) 72
immunosuppressive therapy (72) 72
patients (72) 72
double-blind (71) 71
plasmapheresis (71) 71
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1697) 1697
Japanese (341) 341
French (42) 42
German (16) 16
Korean (16) 16
Russian (14) 14
Spanish (10) 10
Polish (7) 7
Chinese (5) 5
Hungarian (2) 2
Portuguese (2) 2
Czech (1) 1
Indonesian (1) 1
Italian (1) 1
Romanian (1) 1
Slovenian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Medicine (United States), ISSN 0025-7974, 09/2017, Volume 96, Issue 39, p. e8159
Rationale: Treatment choices are limited, when deciding how to manage thyrotoxicosis and moderate to severe Graves ophthalmopathy (GO) with suspected optic... 
Graves ophthalmopathy, intravenous methylprednisolone pulse therapy, methimazole | DIAGNOSIS | MANAGEMENT | intravenous methylprednisolone pulse therapy | Graves ophthalmopathy | ANTITHYROID DRUGS | GUIDELINES | PHARMACODYNAMICS | methimazole | PREDNISOLONE | MEDICINE, GENERAL & INTERNAL | PHARMACOKINETICS | HEPATITIS | STEROID-THERAPY | HEPATOTOXICITY | Methimazole - administration & dosage | Glucocorticoids - administration & dosage | Thyrotoxicosis - complications | Humans | Optic Nerve Diseases - diagnosis | Medication Therapy Management | Methylprednisolone - adverse effects | Symptom Assessment - methods | Dose-Response Relationship, Drug | Optic Nerve Diseases - complications | Methimazole - adverse effects | Female | Thyrotoxicosis - physiopathology | Graves Ophthalmopathy - drug therapy | Glucocorticoids - adverse effects | Liver Function Tests | Antithyroid Agents - adverse effects | Optic Nerve Diseases - physiopathology | Treatment Outcome | Antithyroid Agents - administration & dosage | Chemical and Drug Induced Liver Injury - physiopathology | Thyrotoxicosis - diagnosis | Chemical and Drug Induced Liver Injury - diagnosis | Graves Ophthalmopathy - diagnosis | Administration, Intravenous | Chemical and Drug Induced Liver Injury - therapy | Aged | Pulse Therapy, Drug - methods | Graves Ophthalmopathy - physiopathology | Methylprednisolone - administration & dosage
Journal Article
Kidney International, ISSN 0085-2538, 08/2006, Volume 70, Issue 4, pp. 732 - 742
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2014, Volume 9, Issue 1, p. e81344
We focus on the role of CD8(+) Treg cell in Intravenous methyl-prednisolone (IVMP) pulse therapy in forty patients with active Class III/IV childhood lupus... 
ACTIVATION | STIMULATION | MULTIPLE-SCLEROSIS | TOLERANCE | MULTIDISCIPLINARY SCIENCES | REGULATORY T-CELLS | MEDIATED SUPPRESSION | INDUCTION | CANCER | GRANZYME-B | ERYTHEMATOSUS | Forkhead Transcription Factors - immunology | RNA, Small Interfering - genetics | Methylprednisolone - therapeutic use | Proteinuria - immunology | Apoptosis - drug effects | Cell Count | Humans | RNA, Small Interfering - pharmacology | Lupus Nephritis - drug therapy | Lupus Nephritis - immunology | Forkhead Transcription Factors - genetics | Administration, Intravenous | Proteinuria - drug therapy | Adolescent | Granzymes - immunology | CD8-Positive T-Lymphocytes - immunology | Pulse Therapy, Drug - methods | Interleukin-10 - immunology | Proteinuria - complications | Lupus Nephritis - complications | Methylprednisolone - administration & dosage | Cell proliferation | Flow cytometry | Therapy | Pediatrics | Nephritis | Nephrology | Intravenous administration | Disease | CD8 antigen | Leukocytes (mononuclear) | Lymphocytes T | Lupus nephritis | Tissues | Methylprednisolone | Granzyme B | Immunology | Lymphocytes | Peripheral blood mononuclear cells | CD25 antigen | Foxp3 protein | Children | Stains | Prednisolone | Lupus | Antigens | Kidneys | Anemia | T cell receptors | Patients | CD4 antigen | Hospitals | Biopsy | Cell number | Interleukin 10 | Nucleosomes | Interferon | Autoimmune diseases | Proteinuria | Apoptosis | Kidney transplantation
Journal Article
Multiple Sclerosis Journal, ISSN 1352-4585, 6/2016, Volume 22, Issue 7, pp. 926 - 934
Background: There is a large unmet need for treatments for patients with progressive multiple sclerosis (MS). Phase 2 studies with cerebrospinal fluid (CSF)... 
clinical trial | Progressive multiple sclerosis | methylprednisolone | magnetization transfer ratio | osteopontin | cerebrospinal fluid | CORD | NEUROSCIENCES | BRAIN | CLINICAL NEUROLOGY | Predictive Value of Tests | Recurrence | Glucocorticoids - administration & dosage | Humans | Middle Aged | Male | Methylprednisolone - adverse effects | Multiple Sclerosis, Chronic Progressive - diagnostic imaging | Recovery of Function | Young Adult | Evoked Potentials, Motor | Inflammation Mediators - cerebrospinal fluid | Time Factors | Adult | Female | Multiple Sclerosis, Chronic Progressive - drug therapy | Glucocorticoids - adverse effects | Multiple Sclerosis, Chronic Progressive - cerebrospinal fluid | Multiple Sclerosis, Chronic Progressive - physiopathology | Bone Density | Administration, Oral | Osteopontin - cerebrospinal fluid | Treatment Outcome | Pulse Therapy, Drug | Disease Progression | Diffusion Tensor Imaging | Magnetic Resonance Imaging | Neurologic Examination | Adolescent | Denmark | Aged | Biomarkers - cerebrospinal fluid | Methylprednisolone - administration & dosage | Multiple sclerosis | Nuclear magnetic resonance--NMR | Osteopontin | Cerebrospinal fluid | Motor evoked potentials | Motor task performance | Methylprednisolone | Side effects | Magnetic resonance imaging | Demyelination | Evoked potentials | Bone density | Bone imaging
Journal Article
Journal Article
International Journal of Molecular Sciences, ISSN 1661-6596, 10/2018, Volume 19, Issue 10, p. 2918
Journal Article
Dermatologic Therapy, ISSN 1396-0296, 09/2019, Volume 32, Issue 5, p. n/a
Steroid pulse therapy has shown satisfactory efficacy and safety in treating pemphigus vulgaris (PV). However, there is a paucity of data about the efficacy... 
methylprednisolone | steroid pulse therapy | pemphigus vulgaris
Journal Article